Patrick Heron
General Partner @ Frazier Healthcare Partners
Menlo Park, United States
Patrick Heron is a Series A investor at Frazier Healthcare Partners in Menlo Park focused on Biotechnology and Therapeutics. Patrick Heron is the Board Director at VentiRX Pharmaceuticals.Mr. Heron became a General Partner with the onset of FH V (2005), having been a partner in Frazier Healthcare IV (2001). Mr. Heron focuses on biotechnology and growth equity opportunities. Mr. Heron joined Frazier Healthcare in 1999 and founded QuatRx Pharmaceuticals, anin-licensor of early-stage clinical development compounds, with its core management team in late 2000. He also led the opening of Frazier Healthcare's Palo Alto office in the summer of 2003. Mr. Heron currently serves on the boards of Avera Pharmaceuticals, Cerexa, Chimerix, Informed Medical Communications, Panomics, QuatRx Pharmaceuticals and Trubion Pharmaceuticals.Prior to joining Frazier Healthcare, Mr. Heron helped develop McKinsey & Co.'s West Coast biotechnology consulting practice after starting his career working with large pharmaceutical clients on the East Coast. His projects included corporate strategy, M&A, product launch, sales force optimization, corporate partnering and research prioritization. Prior to joining McKinsey, Mr. Heron also worked with Massachusetts General Hospital in evaluating spin-off opportunities and with Cetus Corporation. He was a Morehead Scholar at the University of North Carolina at Chapel Hill and holds an M.B.A. from Harvard Business School.
- Total investments:
- 17
- Last investment:
- Lead investor:
- 35%
Last updated:
For AI agents: llms.txt
Industries Patrick Heron invests in
Stages Patrick Heron invests in
Countries Patrick Heron invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 12 (71%)
- Therapeutics 9 (53%)
- Health Care 7 (41%)
- Pharmaceutical 6 (35%)
- Medical 4 (24%)
Stage
- Series A 7 (41%)
- Series B 4 (24%)
- Series C 2 (12%)
- Funding Round 2 (12%)
- Series F 1 (6%)
Country
- United States 9 (53%)
- China 1 (6%)
- Canada 1 (6%)
- Germany 1 (6%)
- Ireland 1 (6%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Tubulis is a biotechnology company that develops antibody-drug conjugates (ADCs) for targeted cancer therapy. The company combines proprietary technologies with disease-specific biological insights to create highly stable and effective protein-drug conjugates. Its platform enables the design of ADCs with improved delivery, reduced toxicity, andenhanced therapeutic potential across various cancer types, including solid and hematologic tumors. Tubulis is advancing a pipeline of experimental drug candidates, such as TUB-040 and TUB-030, which are currently being evaluated in clinical settings for cancers like ovarian and lung cancer. The company also collaborates with industry partners and leverages its proprietary conjugation technologies to expand the scope and effectiveness of targeted oncology treatments. | $400.6M / Series C / Oct 15, 2025 | ||
| Alpha9 Theranostics is a clinical-stage biopharmaceutical company. | $175M / Series C / Oct 23, 2024 | ||
| Alpha9 Theranostics is a clinical-stage biopharmaceutical company. | $75M / Series B / Dec 14, 2022 | ||
| MBX Biosciences is a biotechnology company that develops therapies to treat rare endocrine diseases where there is inadequate treatment available. It focuses on the discovery, development, and commercialization of first-in-class endocrine therapeutics. | $115M / Series B / Nov 14, 2022 | ||
|
SanReno Therapeutics
|
SanReno Therapeutics develop, manufacture and commercialize kidney disease therapies in the People’s Republic of China, Hong Kong, Macau, Taiwan and Singapore (the “Territory”). SanReno Therapeutics formed with JV of Chinook Therapeutics and Frazier Healthcare Partners and Pivotal bioVenture Partners China. | $40M / Nov 30, 2021 | |
| HilleVax is a biopharmaceutical company that focuses on the development and commercialization of novel vaccines. HilleVax was founded in 2021 and was headquartered in Boston, Massachusetts. | $135M / Venture - Series Unknown / Sep 08, 2021 | ||
| MBX Biosciences is a biotechnology company that develops therapies to treat rare endocrine diseases where there is inadequate treatment available. It focuses on the discovery, development, and commercialization of first-in-class endocrine therapeutics. | $34.6M / Series A / Jul 27, 2020 | ||
| Passage Bio is a fully integrated gene therapy company with a mission to develop a portfolio of five life-transforming AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases. The company is based in Philadelphia, PA and has a research, collaboration and license agreement with the University of Pennsylvaniaand its Gene Therapy Program (GTP) as well as the Orphan Disease Center (ODC). Pursuant to the research collaboration, GTP conducts IND-enabling preclinical work, and Passage Bio is responsible for clinical development, regulatory, manufacturing and commercialization of all product candidates. The ODC is responsible for natural history studies, KOL engagement, and patient advocacy outreach. | $110M / Series B / Sep 04, 2019 | ||
| Passage Bio is a fully integrated gene therapy company with a mission to develop a portfolio of five life-transforming AAV-delivered therapeutics for the treatment of rare monogenic central nervous system diseases. The company is based in Philadelphia, PA and has a research, collaboration and license agreement with the University of Pennsylvaniaand its Gene Therapy Program (GTP) as well as the Orphan Disease Center (ODC). Pursuant to the research collaboration, GTP conducts IND-enabling preclinical work, and Passage Bio is responsible for clinical development, regulatory, manufacturing and commercialization of all product candidates. The ODC is responsible for natural history studies, KOL engagement, and patient advocacy outreach. | $115.5M / Series A / Feb 15, 2019 | ||
| Recida Therapeutics is a Biotechnology company. | $8.5M / Series A / Feb 07, 2019 | ||
| See all 17 investments → | |||
Co-Investors
Frazier Healthcare Partners is a private equity firm that provides investment capital to the pharmaceutical, healthcare services, and medical products sectors. The firm operates through two main strategies: Growth Buyout, which focuses on healthcare services and pharmaceutical businesses, and Life Sciences, which invests in biopharmaceutical companies. The firm partners with industry executives and professionals to scale businesses across the healthcare sector.
Frazier Healthcare Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Nathan Every
General Partner
|
|||
|
Patrick Heron
General Partner
|
|||
Tadataka Yamada
Senior Entrepreneur in Residence
|
|||
Alan D. Frazier
Managinig Partner, Founder & Chairman
|
|||
Bob Baltera
Entrepreneurs In Residence
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Patrick Heron invest in?
Patrick Heron invests primarily in Biotechnology, Therapeutics and Health Care startups, most often at Series A and Series B stage. Most of the 17 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Patrick Heron?
Public channels for Patrick Heron include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Patrick Heron last invest?
The most recent investment recorded for Patrick Heron closed in Oct 2025. Shizune tracks 17 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
